Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258998 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL8117010 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL60323 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL8587285 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL2279600 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL17061382 | 0.98 | TDP1 (0.66) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL60713 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL13893402 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL421756 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL426635 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612172-B1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LTD (IN) | 2025-04-09 | — | — | EP | disclosed |
| US-11680078-B2 | Anticancer compounds | GODAVARI BIOREFINERIES LTD. (IN) | 2023-06-20 | — | — | US | disclosed |
| US-20220389046-A1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LIMITED | 2022-12-08 | — | — | US | disclosed |
| US-11084843-B2 | Anticancer compounds | GODAVARI BIOREFINERIES LTD. (IN) | 2021-08-10 | — | — | US | disclosed |
| EP-3612172-A2 | ANTICANCER COMPOUNDS | Godavari Biorefineries Ltd. (IN) | 2020-02-26 | — | — | EP | disclosed |
| US-20190284222-A1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LTD. (IN) | 2019-09-19 | — | — | US | disclosed |
| US-20190153021-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2018193476-A2 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LIMITED (IN) | 2018-10-25 | — | — | WO | disclosed |
| WO-2017100153-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | BOARD OF REGENTS | 2005-01-06 | — | — | US | disclosed |
| US-6753414-B2 | PREPARING NATURALLY OCCURRING SAPONINS SUCH AS OSW-L | UNIVERSITY OF IOWA RESEARCH FOUNDATION, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030069214-A1 | Process for preparing saponin compounds | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-04-10 | — | — | US | disclosed |
| WO-1998040390-A2 | OLIGOSACCHARIDES AND THE DERIVATIVES THEREOF, CHEMO-ENZYMATIC METHOD FOR THE PRODUCTION THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| US-4859767-A | Glucosylmoranoline derivatives and use thereof for inhibiting increase in blood sugar levels | NIPPON SHINYAKU CO., LTD. (JP) | 1989-08-22 | — | — | US | disclosed |
| US-RE31512-E | SISOMICIN BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-31 | — | — | US | disclosed |
| US-4235888-A | SISOMYCIN-TYPE ANTIBIOTICS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-25 | — | — | US | disclosed |
| EP-0007996-A1 | 4,6-Di-0-(Aminoglycosyl)-1,3-diaminocyclitols, process for their preparation and pharmaceutical compositions containing them | BAYER AG (DE) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284222-A1 | ANTICANCER COMPOUNDS | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
| US-20190153021-A1 | THERAPEUTIC COMPOUNDS | F12, F3, SLC10A1 | TDP1 3881/4885ABCB1 33/4885POLB 3839/4885 |
| US-20030069214-A1 | Process for preparing saponin compounds | LSS, CYP51A1, CYP4F11 | TDP1 2989/4885ABCB1 2020/4885POLB 2854/4885 |
| US-20050004044-A1 | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics | OSBP2, OSBP, OSBPL3 | TDP1 3331/4885ABCB1 2719/4885POLB 3270/4885 |
| US-11680078-B2 | Anticancer compounds | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
| US-20220389046-A1 | ANTICANCER COMPOUNDS | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
| US-11084843-B2 | Anticancer compounds | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.